Kinetic Concepts, Inc. today launched its CelluTome™ Epidermal Harvesting System in Europe. The CelluTome™ System provides an automated, precise and reproducible process of harvesting autologous epidermal tissue for grafting that has been shown to aid closure of acute and chronic wounds.
“This technology is revolutionary because, for the first time, it takes grafting outside the OR and allows us to perform epidermal grafting in a minimally invasive way,” said Keith Harding, CBE, FRCGP, FRCP, FRCS, Dean of Clinical Innovation, Cardiff University School of Medicine. “It enhances our ability to help chronic wounds close when historically these have been difficult and time-consuming to treat.”
In mid June, approximately 300 healthcare professionals from across Europe, the Middle East and Asia attended the International Surgical Wound Forum (ISWF) in Edinburgh, Scotland. As part of a comprehensive clinical program, participants learnt about the science and process for epidermal grafting using micrografts harvested with the CelluTome™ System and discussed patient case studies.
“Using epidermal micrografts harvested with the CelluTome™ System, we now have the ability to promote healing and wound closure over freshly granulated tissue with minimal damage to the donor site,” said Ron Silverman, M.D., chief medical officer, KCI. “For patients, this means that we aren’t creating a new wound to save another.”
The CelluTome™ System enables wound care physicians to harvest and facilitate epidermal grafts, while minimizing donor site complications. The simplicity of the system makes the benefits of epidermal grafting accessible to a much broader range of clinicians and patients than before.
For more information about KCI and the CelluTome™ System, please visit www.kci-medical.com.
About KCI
Kinetic Concepts Inc. (KCI) is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 75 countries around the world. KCI, along with LifeCell Corporation and Systagenix Wound Management, form one globally diversified wound care, biologics and regenerative medicine company, committed to advancing the science of medicine to reduce complications, speed healing and improve patient lives. Headquartered in San Antonio, Texas, the company is a leader in the medical technology industry with the most comprehensive offering of best-in-class surgical and chronic wound therapies. Additional information about KCI and its products is available at www.KCI1.com.
